Moderna
MRNA
915 hedge funds and large institutions have $29.1B invested in Moderna in 2022 Q3 according to their latest regulatory filings, with 80 funds opening new positions, 302 increasing their positions, 354 reducing their positions, and 127 closing their positions.
163% more call options, than puts
Call options by funds: $4.77B | Put options by funds: $1.81B
1.7% more ownership
Funds ownership: 61.49% → 63.19% (+1.7%)
7% less funds holding
Funds holding: 981 → 915 (-66)
15% less repeat investments, than reductions
Existing positions increased: 302 | Existing positions reduced: 354
15% less capital invested
Capital invested by funds: $34.4B → $29.1B (-$5.26B)
21% less funds holding in top 10
Funds holding in top 10: 24 → 19 (-5)
37% less first-time investments, than exits
New positions opened: 80 | Existing positions closed: 127
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$463M |
| 2 |
Mawer Investment Management
Calgary,
Alberta, Canada
|
+$275M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$129M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$74.8M |
| 5 |
Amundi
Paris,
France
|
+$67.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$229M |
| 2 |
Renaissance Technologies
New York
|
-$185M |
| 3 |
BlackRock
New York
|
-$124M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$105M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$85.1M |
MRNA Hedge Fund Activity: Q3 2022 in Review
915 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q3 2022, worth a combined $29.1B — down 15% from $34.4B a quarter earlier.
Sellers outnumbered buyers: 127 funds closed out of MRNA and 80 opened new positions — a net loss of 47 holders — while 354 trimmed existing stakes and 302 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $463M. The largest seller was Goldman Sachs, cutting an estimated $229M.
- 915 institutional investors held Moderna (MRNA) as of Q3 2022, down from 981 in Q2 2022.
- Funds reported $29.1B of Moderna stock for Q3 2022, down 15% quarter-over-quarter.
- 80 funds opened new Moderna positions in Q3 2022 and 127 closed out, a net change of -47 holders.
- The largest Moderna buyer in Q3 2022 was T. Rowe Price Associates, an estimated $463M added.
- The largest Moderna seller in Q3 2022 was Goldman Sachs, an estimated $229M sold.
Based on aggregated 13F filings for Q3 2022.